Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative antibiotics. This company primarily aims to address the critical need for novel treatments against bacterial infections, particularly those caused by strains that are resistant to multiple drugs. Acurx's lead antibiotic candidates, developed using a proprietary antibacterial platform, target serious infections like Clostridium difficile, a bacteria associated with high morbidity and recurring infections. Engaged in the pharmaceutical and healthcare sector, Acurx plays a crucial role in combatting antibiotic resistance, a growing public health concern globally. By advancing its portfolio of antibiotics through clinical trials, the company contributes significantly to medical science and the potential for improved patient outcomes. Acurx Pharmaceuticals Inc., though relatively newer in the expansive pharmaceutical landscape, holds importance for its commitment to pioneering research and addressing unmet medical needs in infectious diseases.